$SGEN 4Q and Full Year 2018 Financial Results. Topline Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the 1Q 2019 httpswww.businesswire.comnewshome20190207005747enSeattleGeneticsReportsFourthQuarterFul

$SGEN 4Q and Full Year 2018 Financial Results. Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the 1Q 2019 https://www.businesswire.com/news/home/20190207005747/en/Seattle-Genetics-Reports-Fourth-Quarter-Ful

16:04 EST 7 Feb 2019 | Odi Bruckman

$SGEN 4Q and Full Year 2018 Financial Results. Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the 1Q 2019 https://www.businesswire.com/news/home/20190207005747/en/Seattle-Genetics-Reports-Fourth-Quarter-Full-Year …

More From BioPortfolio on "$SGEN 4Q and Full Year 2018 Financial Results. Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the 1Q 2019 https://www.businesswire.com/news/home/20190207005747/en/Seattle-Genetics-Reports-Fourth-Quarter-Ful"